GSK plc has scored a notch on the respiratory syncytial virus (RSV) vaccine development leaderboard, beating rival Pfizer Inc. to a younger adult population. The US Food and Drug Administration on 7 June approved GSK’s RSV vaccine Arexvy in adults aged 50-59 who have medical conditions that put them at increased risk of severe RSV.
Key Takeaways
- GSK beat Pfizer to a new younger patient population for its RSV vaccine Arexvy with US FDA approval in adults aged 50-59.
The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) is expected to discuss vaccination recommendations...






